Aortic Valve Stenosis Clinical Trials

Find Aortic Valve Stenosis Clinical Trials Near You

InvesTigAtion of the reVersIbility of caRdiac Conduction disturbancEs Following Percutaneous Aortic ValvE Implantation in Patients With Severe aoRtic StEnosis: The TAVI-REVERSE Study

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The management of patients with conduction disturbances (CDs) after transcatheter aortic valve implantation (TAVI) is unclear, especially in those with de novo electrocardiographic CDs (ECG-CDs) such as left bundle branch block. In this study, the investigators will evaluate the incidence of retrogradation of infra-Hisian CDs in patients with de novo ECG-CDs and positive electrophysiological study (EPS) 3-7 days following TAVI. In addition, the investigators will evaluate the need for cardiac pacing and the incidence of clinical events in patients with negative EPS performed 3-7 days following TAVI. In this multicenter, longitudinal, prospective study, patients with clinical indication of EP study due to new-onset ECG-CDs after TAVI will be included. A permanent pacemaker will be implanted in patients with positive EPS and a second EPS will be performed in 30-45 days. Additionally, these patients will undergo 4-week continuous monitoring using the ePatch (Philips) long-term Holter recorder, to identify episodes of paroxysmal complete atrioventricular block. Patients with negative EP study will undergo clinical follow-up and continuous monitoring for 4 weeks.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with indication for electrophysiological (EP) study after TAVI implantation according to European Guidelines. Patients must have persistent electrocardiographic conduction disturbances (ECG-CDs) that are present from day 2 after TAVI implantation (≥ 48h post-procedure):

• De novo LBBB with QRS complex \>150ms and/or PR interval ≥240ms.

• QRS widening or post-procedural PR lengthening \> 20ms in patients with baseline ECG-CDs.

Locations
Other Locations
Spain
Hospital Universitari de Bellvitge
RECRUITING
L'hospitalet De Llobregat
Contact Information
Primary
Guillem Muntané Carol, MD, PhD
gmuntanec@bellvitgehospital.cat
+342607500
Time Frame
Start Date: 2024-06-17
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 209
Treatments
Experimental: Positive initial (3-7 days following TAVI) electrophysiological study (EP+)
Permanent pacemaker implantation. Continuous ECG monitoring during 4 weeks. Second EP study 30-45 days after TAVI.
Other: Negative initial (3-7 days following TAVI) electrophysiological study (EP-)
Continuous ECG monitoring during 4 weeks.
Sponsors
Leads: Institut d'Investigació Biomèdica de Bellvitge
Collaborators: Hospital Vall d'Hebron, Hospital Clinico Universitario de Santiago, Hospital Universitario La Paz, Hospital Universitario Marqués de Valdecilla, Hospital Universitari de Bellvitge, Hospital Universitario Ramon y Cajal, Hospital Clínico Universitario de Valladolid, Hospital Universitario Central de Asturias, Hospital Universitario A Coruna Spain

This content was sourced from clinicaltrials.gov